AI BriefingNarasimhan Joins the Board
Key point
Novartis CEO Vas Narasimhan has been appointed as a board member of Anthropic.
Details
Anthropic's Long-Term Benefit Trust has appointed Vas Narasimhan, CEO of Novartis and a physician-scientist, as a board member.
Narasimhan emphasized that AI is one of the areas with the greatest potential to improve quality of life for humanity in the healthcare and life sciences fields. Drawing on his experience developing and approving more than 35 new drugs in the heavily regulated pharmaceutical industry, he will help contribute to deploying powerful technology safely and at scale.
As a Public Benefit Corporation, Anthropic's board is elected by shareholders and the Long-Term Benefit Trust. With this appointment, Trust-appointed directors now hold a majority of the board, which helps ensure the company's growth maintains a responsible balance between financial success and its public-benefit mission of developing AI for humanity.
Anthropic's current board includes Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell.
This summary was generated automatically by AI. Check the original for the author's claims and context. Copyright belongs to the original author.
Our guide explains how the AI works. Report summary errors, attribution issues, or removal requests via Contact.
Related
US Appeals Court Upholds Pentagon Blacklisting of Anthropic as Supply Chain Risk